Search

Your search keyword '"Bielefeld, Philip"' showing total 113 results
Start Over Author "Bielefeld, Philip"
113 results on '"Bielefeld, Philip"'

1. Sarcoïdose osseuse : étude cas-témoin multicentrique

Author

Ben Hassine, Imen, Rein, Christopher, Comarmond, Cloé, Glanowski, Camille, Saidenberg-Kermanac’h, Nathalie, Meunier, Benoît, Schleinitz, Nicolas, Chanson, Noémie, Sacré, Karim, Scherlinger, Marc, Richez, Christophe, Hirschi, Sandrine, Groh, Matthieu, Devilliers, Hervé, Bielefeld, Philip, Saadoun, David, Chapelon-Abric, Catherine, Arnaud, Laurent, and Cacoub, Patrice

Published
2020
Full Text
View/download PDF

2. Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients

Author

Ben Hassine, Imen, Rein, Christopher, Comarmond, Cloé, Glanowski, Camille, Saidenberg-Kermanac’h, Nathalie, Meunier, Benoît, Schleinitz, Nicolas, Chanson, Noémie, Sacré, Karim, Scherlinger, Marc, Richez, Christophe, Hirschi, Sandrine, Groh, Matthieu, Devilliers, Hervé, Bielefeld, Philip, Saadoun, David, Chapelon-Abric, Catherine, Arnaud, Laurent, and Cacoub, Patrice

Published
2019
Full Text
View/download PDF

3. Induction failure in granulomatosis with polyangiitis: a nationwide case-control study of risk factors and outcomes.

Author

Sorin, Boris, Iudici, Michele, Guerry, Mary-Jane, Samson, Maxime, Bielefeld, Philip, Maillet, Thibault, Nouvier, Mathilde, Karras, Alexandre, Meyer, Lara, Lavigne, Christian, Régent, Alexis, Durel, Cécile-Audrey, Fabre, Marc, Charles, Pierre, Raimbourg, Quentin, Lanteri, Aurélia, Pugnet, Grégory, Rivière, Frédéric, Chambrun, Marc Pineton de, and Cacoub, Patrice

Subjects
RITUXIMAB, DRUG efficacy, DISEASE progression, CASE-control method, RETROSPECTIVE studies, GRANULOMATOSIS with polyangiitis, TREATMENT failure, RISK assessment, COMPARATIVE studies, CYCLOPHOSPHAMIDE, DESCRIPTIVE statistics, SALVAGE therapy, IMMUNOSUPPRESSIVE agents, CREATININE, DISEASE remission
Abstract

Objective To identify characteristics of granulomatosis with polyangiitis (GPA) associated with induction failure, describe salvage therapies and their efficacy. Methods We conducted a nationwide retrospective case-control study of GPA with induction failure between 2006 and 2021. Each patient with induction failure was randomly paired to three controls matched for age, sex and induction treatment. Results We included 51 patients with GPA and induction failure (29 men and 22 women). At induction therapy, median age was 49 years. Twenty-seven patients received intravenous cyclophosphamide (ivCYC) and 24 rituximab (RTX) as induction therapy. Patients with ivCYC induction failure more frequently had PR3-ANCA (93% vs 70%, P  = 0.02), relapsing disease (41% vs 7%, P  < 0.001) and orbital mass (15% vs 0%, P  < 0.01) compared with controls. Patients with disease progression despite RTX induction therapy more frequently had renal involvement (67% vs 25%, P  = 0.02) with renal failure (serum creatinine >100 µmol/l in 42% vs 8%, P  = 0.02) compared with controls. After salvage therapy, remission was achieved at 6 months in 35 (69%) patients. The most frequent salvage therapy was switching from ivCYC to RTX (or vice versa), showing an efficacy in 21/29 (72%). Remission was achieved in nine (50%) patients with inappropriate response to ivCYC, while in patients with progression after RTX induction, remission was achieved in four (100%) who received ivCYC (with or without immunomodulatory therapy), but only in three (50%) after adding immunomodulatory therapy alone. Conclusion In patients with induction failure, characteristics of GPA, salvage therapies and their efficacy vary according to induction therapy and failure modality. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

4. Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients

Author

Maalouf, Georgina, primary, Andrillon, Anaïs, additional, Leclercq, Mathilde, additional, Sève, Pascal, additional, Bielefeld, Philip, additional, Gueudry, Julie, additional, Sené, Thomas, additional, Titah, Cherif, additional, Moulinet, Thomas, additional, Rouvière, Bénédicte, additional, Sène, Damien, additional, Desbois, Anne-Claire, additional, Domont, Fanny, additional, Touhami, Sara, additional, Thibault, Thomas, additional, Chamieh, Carolla El, additional, Cacoub, Patrice, additional, Kodjikian, Laurent, additional, Biard, Lucie, additional, Bodaghi, Bahram, additional, and Saadoun, David, additional

Published
2022
Full Text
View/download PDF

5. Anti–Tumor Necrosis Factor α versus Tocilizumab in the Treatment of Refractory Uveitic Macular Edema

Author

Leclercq, Mathilde, primary, Andrillon, Anaïs, additional, Maalouf, Georgina, additional, Sève, Pascal, additional, Bielefeld, Philip, additional, Gueudry, Julie, additional, Sené, Thomas, additional, Moulinet, Thomas, additional, Rouvière, Bénédicte, additional, Sène, Damien, additional, Desbois, Anne-Claire, additional, Domont, Fanny, additional, Touhami, Sara, additional, El Chamieh, Carolla, additional, Cacoub, Patrice, additional, Bodaghi, Bahram, additional, Biard, Lucie, additional, and Saadoun, David, additional

Published
2022
Full Text
View/download PDF

6. Anti-TNF-α versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French Uveitis Network

Author

Leclercq, Mathilde, Andrillon, Anaïs, Maalouf, Georgina, Sève, Pascal, Bielefeld, Philip, Gueudry, Julie, Sené, Thomas, Moulinet, Thomas, Rouvière, Bénédicte, Sène, Damien, Desbois, Anne-Claire, Domont, Fanny, Touhami, Sara, El Chamieh, Carolla, Cacoub, Patrice, Bodaghi, Bahram, Biard, Lucie, Saadoun, David, CHU Rouen, Normandie Université (NU), Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de biostatistique et information médicale de l’hôpital Saint Louis (Equipe ECSTRA) (SBIM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut national du cancer [Boulogne] (INCA)-Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université de Paris (UP), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Interne et Médecine Générale [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Equipe 2 : ECSTRA - Epidémiologie Clinique, STatistique, pour la Recherche en Santé (CRESS - U1153), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Cité (UPCité), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), and Moulinet, Thomas

Subjects
safety, tocilizumab, uveitic macular edema, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, [SDV.IMM] Life Sciences [q-bio]/Immunology, efficacy, [SDV.IMM]Life Sciences [q-bio]/Immunology, anti-TNF-α agents, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; ObjectiveTo analyze the factors associated with response (control of ocular inflammation and corticosteroid sparing effect) to biologics (anti-TNF-α agents and tocilizumab) in patients with refractory uveitic macular edema.DesignMulticenter retrospective observational study.SubjectsAdult patients with uveitic macular edema refractory to systemic corticosteroids and/or disease modifying anti-rheumatic drugs.MethodsPatients received anti-TNF-α agents [IFX 5 mg/kg at weeks 0, 2, 6 and every 4-6 weeks (n=69) and ADA 40 mg/14 days (n=80)] and tocilizumab [8 mg/kg every 4 weeks intravenously (n=39) and 162 mg/week subcutaneously (n=16)].Main Outcome MeasuresAnalysis of complete and partial response rates, relapse rate, low vision (visual acuity in at least one eye ≥ 1 LogMAR), corticosteroid sparing effect and adverse events at 6 months.Results204 patients (median age of 40 years [28-58] with 42.2% of men) were included. Main etiologies of uveitis included Behçet’s disease (17.2%), birdshot chorioretinopathy (11.3%) and sarcoidosis (7.4%). The overall response rate at 6 months was of 46.2% (21.8% of complete response) with anti-TNF-α agents and 58.5% (35.8% of complete response) with tocilizumab. In multivariate analysis, treatment with tocilizumab (OR 2.10 [95% CI 1.06–4.06], p=0.03) was independently associated with complete response of uveitic macular edema, compared to anti-TNF-α agents. Anti-TNF-α agents and tocilizumab did not differ significantly in terms of relapse rate (HR=1.00 [0.31-3.18], p=0.99) or occurrence of low vision (OR=1.02 [0.51-2.07], p=0.95) or corticosteroid-sparing effect (p=0.29). Adverse events were reported in 20.6% of patients, including 10.8% of serious adverse events.ConclusionsTocilizumab seems to improve complete response of uveitic macular edema compared to anti-TNF-α agents.

Published
2021

7. Clinicopathologic characteristics, treatment, and outcomes of tubulointerstitial nephritis and uveitis syndrome in adults: A national retrospective strobe-compliant study

Author

Legendre, Mathieu, Devilliers, Hervé, Perard, Laurent, Groh, Matthieu, Nefti, Habdelamid, Dussol, Bertrand, Trad, Salim, Touré, Fatouma, Abad, Sébastien, Boffa, Jean-Jacques, Frimat, Luc, Torner, Stéphane, Seidowsky, Alexandre, Massy, Ziad André, Saadoun, David, Rieu, Virginie, Schoindre, Yoland, Heron, Emmanuel, Frouget, Thierry, Lionet, Arnaud, Glowacki, François, Arnaud, Laurent, Mousson, Christiane, Besancenot, Jean-François, Rebibou, Jean-Michel, and Bielefeld, Philip

Published
2016
Full Text
View/download PDF

8. Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network

Author

Vallet, Hélène, Seve, Pascal, Biard, Lucie, Baptiste Fraison, Jean, Bielefeld, Philip, Perard, Laurent, Bienvenu, Boris, Abad, Sébastien, Rigolet, Aude, Deroux, Alban, Sene, Damien, Perlat, Antoinette, Marie, Isabelle, Feurer, Elodie, Hachulla, Eric, Fain, Olivier, Clavel, Gaëlle, Riviere, Sophie, Bouche, Pierre-Alban, Gueudry, Julie, Pugnet, Gregory, Le Hoang, Phuc, Resche Rigon, Matthieu, Cacoub, Patrice, Bodaghi, Bahram, and Saadoun, David

Published
2016
Full Text
View/download PDF

13. Is IL-6 the Right Target in COVID-19 Severe Pneumonia?

Author

Blot, Mathieu, primary, Bourredjem, Abderrahmane, additional, Binquet, Christine, additional, Piroth, Lionel, additional, Blot, Mathieu, additional, Quenot, Jean-Pierre, additional, Charles, Pierre-Emmanuel, additional, Aptel, François, additional, Prin, Sébastien, additional, Andreu, Pascal, additional, Labruyère, Marie, additional, Dargent, Auguste, additional, Nguyen, Maxime, additional, Bouhemad, Belaid, additional, Georges, Marjolaine, additional, Bonniaud, Philippe, additional, Beltramo, Guillaume, additional, Buisson, Marielle, additional, Bonnotte, Bernard, additional, Bielefeld, Philip, additional, Barben, Jeremy, additional, Putot, Alain, additional, Monier, Serge, additional, Large, Audrey, additional, Mouries-Martin, Suzanne, additional, Devilliers, Hervé, additional, Chavanet, Pascal, additional, and Guilhem, Alexandre, additional

Published
2021
Full Text
View/download PDF

14. Evaluating the cost-consequence of a standardized strategy for the etiological diagnosis of uveitis (ULISSE study)

Author

de Parisot, Audrey, Jamilloux, Yvan, Kodjikian, Laurent, Errera, Marie-Hélène, Sedira, Neila, Heron, Emmanuel, Perard, Laurent, Cornut, Pierre-Loic, Schneider, Christelle, Rivière, Sophie, Ollé, Priscille, Pugnet, Grégory, Cathebras, Pascal, Manoli, Pierre, Bodaghi, Bahram, Saadoun, David, Baillif, Stéphanie, Tieulié, Nathalie, André, Marc, Chiambaretta, Fédéric, BONIN, Nicolas, Bielefeld, Philip, Bron, Alain, Mouriaux, Frédéric, Bienvenu, Boris, Amamra, Nassira, Guerre, Pascale, Decullier, Evelyne, Sève, Pascal, ULISSE, ., Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Sève, Pascal, Hospices Civils de Lyon (HCL), Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (CHNO), Equipe mobile de Gériatrie, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Pierre-Paul Riquet Hospital, Poison Control Center, Toulouse-Purpan University Hospital, Toulouse, France., Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Desgenettes Hospital, Partenaires INRAE, CHU Limoges, CHU Rouen, Normandie Université (NU), La Conception, Bicêtre Hospital, South Hospital, Rabelais Center, Hôpital Montchanin, Centre Hospitalier Universitaire [Rennes], Hôpital Chalon-sur-Saône, Hôpital Nantes, and The French Ministry of Health (PHRC 2009).

Subjects
Male, Bacterial Diseases, Pediatrics, Organes des sens, Pathology and Laboratory Medicine, Treponematoses, law.invention, Diagnostic Radiology, 0302 clinical medicine, Randomized controlled trial, law, Medicine and Health Sciences, Prospective Studies, Practice Patterns, Physicians', Prospective cohort study, health care economics and organizations, ComputingMilieux_MISCELLANEOUS, Serodiagnosis, Multidisciplinary, Ophthalmologists, Radiology and Imaging, Middle Aged, Magnetic Resonance Imaging, 3. Good health, Serology, Infectious Diseases, Radiological weapon, Medicine, Female, France, Uveitis, Research Article, Neglected Tropical Diseases, Adult, medicine.medical_specialty, Imaging Techniques, Science, Urology, Sensory Organs, MEDLINE, Sexually Transmitted Diseases, Tuberculin, Médecine humaine et pathologie, Research and Analysis Methods, Microbiology, 03 medical and health sciences, Diagnostic Medicine, Virology, medicine, Humans, Syphilis, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, 030203 arthritis & rheumatology, business.industry, Genitourinary Infections, Biology and Life Sciences, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, medicine.disease, Tropical Diseases, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Ophthalmology, Viral Disease Diagnosis, 030221 ophthalmology & optometry, Etiology, Human health and pathology, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; MAIN OBJECTIVE: To prospectively assess the cost-consequence of a standardized diagnostic strategy as to compared to an open one for the etiological diagnosis of uveitis. DESIGN: This was a prospective, non-inferiority, multicentre, randomized controlled trial. METHODS: We included all consecutive patients with uveitis who had visited at least one of the Departments of Ophthalmology. In the standardized group, patients had a minimal work-up regardless of the type of uveitis (including evaluation of the CBC, ESR, C-reactive protein, tuberculin skin test, syphilis serology and chest X-ray). Depending on ophthalmological findings, further investigations could be performed. In the open strategy, ophthalmologists were free to order any kind of investigation. The main outcome was the mean cost per patient of each strategy. RESULTS: 903 uveitis patients were included from January, 2010 to May, 2013. The mean cost per patient of the standardized strategy was 182.97 euros [CI 95% (173.14; 192.80)], and the mean cost per patient of the open strategy was 251.75 euros [CI 95% (229.24; 274.25)]. Therefore, the mean cost per patient of the standardized strategy was significantly lower than the mean cost per patient of the open strategy (p

Published
2020

16. Quality of life in patients with uveitis: data from the ULISSE study (Uveitis: cLInical and medico-economic evaluation of a Standardised Strategy for the Etiological diagnosis)

Author

Bertrand, Pierre-jean, primary, Jamilloux, Yvan, additional, Kodjikian, Laurent, additional, Errera, Marie-Helene, additional, Perard, Laurent, additional, Pugnet, Gregory, additional, Tieulie, Nathalie, additional, Andre, Marc, additional, Bielefeld, Philip, additional, Bron, Alain M, additional, Decullier, Evelyne, additional, Bin, Sylvie, additional, and Seve, Pascal, additional

Published
2020
Full Text
View/download PDF

17. Tocilizumab for refractory dysthyroid myopathy (RDM): A monocenter observational study of 8 patients

Author

Bielefeld, Philip, Baudin, Florian, Blanc, Julie, Bron, Alain, Mouries-Martin, Suzanne, Bouvet, Romain, Devilliers, Hervé, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), and Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Abstract

Background: Dysthyroïd myopathy (DM) refers to Graves’ ophthalmopathy (GO) in 90% of the cases but can also be observed with hypothyroidism, and is responsible for orbital fat and muscles inflammation. In those patients with euthyroidism and no thyroid receptor antibody, a strong argument for DM can be the aspect of the extra ocular muscles. In myositis of other causes, muscle insertions are increased in size. In DM, the insertions are respected and not increased in volume in magnetic resonance imaging. This was the case of our eight patients. Objectives: To describe the efficacy of Tocilizumab (TCZ) in RDM in 8 patients Methods: We conducted a monocenter study of 8 patients with RDM refractory to conventional treatment scheme All patients have been treated following the EUGOGO (European Group on Graves’ Orbitopathy) scheme, which consists in weekly infusions of 500 mg prednisolone (4 to 6) followed by weekly infusions of 250 g (4 to 6). One patient had received before oral prednisolone, which is known to be less effective and no other immunosuppressive therapy. The aim was to reduce the clinical activity score (CAS) of the disease to a score of 1 (score composed of 7 items) Results: We studied 8 female patients (16 eyes); mean age at diagnosis 64,37±9,37 years. All patients had normal thyroid function at diagnosis.Three patients had a previous history of hashimoto’s thyroiditis and the other 5 had no immunological abnormalities. The duration of orbitopathy between first supposed manifestations and therapy onset was 5,7 months +/- 2,3. TCZ was introduced at the end of the steroid pulses, or before, during steroid therapy, in 2 patients who did not improve at all their ocular status after 3 steroid infusions. TCZ was used intravenously as a monotherapy, at the classical dosage of 8 mg/kg per infusion, with no other immunosuppressives. According to the classification of severity of the EUGOGO group using the CAS 1, before TCZ, 1 had severe (n=2 eyes) or moderate (n= 14 eyes) disease. Moreover, patients presented exophthalmos (n=16 eyes), strabismus (n=16 eyes), muscle inflammation and volume increase at MRI and severe optic neuropathy (n=1). After a mean of 4 pulses (extremes 1 to 7), all patients experienced improvement with TCZ withdrawal in all due to complete remission in 3 and regression in ocular inflammation in 5. Unfortunately, one patient relapsed two months after the 6th TCZ infusion, despite of initial complete remission and was treated with 4 weekly infusions of rituximab at 375 mg/m 2 with a very good response three months later. Only one patient experienced a severe anal abcess after the first TCZ infusion leading to treatment interruption, but with a good improvement of DM. Improvement of ocular parameters with TCZ therapy. Data are expressed as mean±SD or median [IQR]. (VA : visual acuity; IOP : intra ocular pressure; CAS : clinical activity score) Before tocilizumab after tocilizumab VA 0,7 (0,3-1) 0,9 (0,7-1) IOP 26,5 +/-7,7 21,1+/-13 CAS 4,25 +/- 1,28 1 Conclusion: TCZ seems to be effective in RDM, as previously reported. In case of ineffectiveness or relapse, rituximab may be effective as well. This questions us about a new treatment scheme, which patients could benefit from biotherapies alone for a better and quicker efficiency? REFERENCES [1] - Dolman PJ. Grading Severity and Activity in Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1):S34-S40

Published
2019

18. Osseous sarcoidosis: a multicenter case-control study

Author

Ben Hassine, Imen, Rein, Christopher, Comarmond, Cloé, Glanowski, Camille, Saidenberg-Kermanac’h, Nathalie, Meunier, Benoit, Schleinitz, Nicolas, Chanson, Noémie, Sacre, Karim, Scherlinger, Marc, Richez, Christophe, Hirschi, Sandrine, Groh, Matthieu, Devilliers, Hervé, Bielefeld, Philip, Saadoun, David, Chapelon-Abric, Catherine, Arnaud, Laurent, Cacoub, Patrice, Immunologie - Immunopathologie - Immunothérapie (I3), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris] (DHU - I2B), CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU), Hôpital d'Instruction des Armées Legouest, Service de Santé des Armées, Service de rhumatologie, inflammation-immunopathologie- biothérapie [CHU Saint-Antoine] (DHU i2B ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Hôpital d'Instruction des Armées Begin, Physiopathologie, Cibles et Thérapies de la Polyarthrite Rhumatoïde, Université Paris 13 (UP13)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Sorbonne Paris Cité (USPC), Aix-Marseille Université - Faculté de médecine (AMU MED), Aix Marseille Université (AMU), Hôpital de la Timone [CHU - APHM] (TIMONE), CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Bordeaux [Bordeaux], CHU Strasbourg, Hôpital Foch [Suresnes], Service de médecine interne et maladies systémiques (SOC 2) [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Immuno-Rhumatologie Moléculaire, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie - Immunopathologie - Immunothérapie [CHU Pitié Salpêtrière] (I3), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Département de médecine interne et immunologie clinique [CHU Pitié-Salpêtrière] (DMIIC), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Trousseau [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU)

Subjects
musculoskeletal diseases, Sarcoidosis, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Bone involvement, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, musculoskeletal system, Osseous manifestations
Abstract

International audience; Objective: To describe the clinical presentation, distribution of lesions, treatment, and outcomes of osseous sarcoidosis.Methods: A French retrospective multicenter study of patients with biopsy-proven sarcoidosis analyzed patients with 1) a biopsy-proven granuloma without caseous necrosis, and either 2) osseous clinical manifestations, or 3) abnormal osseous imaging. Sarcoidosis patients with osseous involvement (cases) were compared with 264 age- and sex-matched sarcoidosis patients with no osseous manifestations (controls).Results: In the osseous sarcoidosis group (n = 88), forty-two (48%) patients had osseous-related symptoms involving the axial (69%) and/or appendicular (58%) skeleton. On imaging, the most commonly affected bones were in the spine (52%), pelvis (42%), hands (22%) and femur (19%). Compared with controls, cases had higher rates of mediastinal (93% vs. 47%) and extra-thoracic lymph node involvement (66% vs. 21%), pulmonary (90% vs. 65%) and cutaneous involvement (44% vs. 23%) (all P < 0.0001), and hypercalcemia (8.5% vs. 2%, P = 0.014). Spleen/liver and gastrointestinal involvement were less frequent in the osseous sarcoidosis group (29% vs. 45%, and 1% vs. 17%, respectively, P < 0.0001). Response rates to with glucocorticoids alone, glucocorticoids plus methotrexate or glucocorticoids plus hydroxychloroquine were 23/44 (52%), 9/13 (69%) and 4/6 (67%), respectively.Conclusion: In patients with osseous sarcoidosis the spine and pelvis were the most commonly affected bones. Compared with controls, cases with osseous sarcoidosis have higher rates of thoracic and extra-thoracic lymph node involvement, pulmonary and cutaneous involvement, and hypercalcemia. Most patients with osseous sarcoidosis had a good response to glucocorticoids in combination with methotrexate or hydroxychloroquine.

Published
2019

19. Recours à la biothérapie dans la prise en charge de la maladie de Behçet dans un service de médecine interne

Author

Wanvoegbe, F.A., Turcu, A., Bach, B., Devilliers, Hervé, Muller, Géraldine, Deschasse, Clémence, Besancenot, Jean-François, Bron, Alain, Bielefeld, Philip, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre hospitalier Universitaire, Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), and Université Bourgogne Franche-Comté [COMUE] (UBFC)

Subjects
Adult, Male, Behçet's disease, Adolescent, Behcet Syndrome, Hospital Departments, Middle Aged, Biological Therapy, Young Adult, biotherapy, Internal Medicine, Humans, Female, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Retrospective Studies
Abstract

BACKGROUND: Behcet's disease (BD) is a recurrent multisystemic disease responsible for occlusive vasculitis with arterial, venous and capillary involvement. The aim of this study was to determine the frequency and the features associated with the use of biotherapy in the management of patients followed in our department for BD. METHODS: This is a retrospective study of patients medical records followed for BD in a department of internal medicine from January 2005 to August 2018. RESULTS: A total of 41 patients were included with a mean age at diagnosis of 42.5+/-12.1 years (range 16 to 63) and a sex ratio men/women of 1.05. Oral and/or genital aphtosis was present in 70.7% of the patients. Other lesions were: ocular (78.0%), articular (46.3%), cutaneous (41.5%), central neurological (34.1%), vascular (26.8%), digestive (7.3%), pericardial (2.4%) and epididymal (2.4%). A biotherapy, interferon alpha and monoclonal antibodies, was used in 15 patients (36.6%), after failure of conventional treatments. The monoclonal antibodies were anti-TNFalpha (infliximab, adalimumab, certolizumab and golimumab) except in one patient for whom ustekinumab was used. Biotherapy was used in 46.9% of the patients with ocular involvement and never used in those patients without ocular involvement (P=0.01). CONCLUSION: Biotherapy is effective and represents a solution to the failures of conventional treatments in severe forms of Behcet's disease with ocular involvement.; Introduction : La maladie de Behçet (MB) est une vascularite occlusive artérielle, veineuse et capillaire responsable d’atteintes multisystémiques. L’objectif de cette étude était de déterminer la fréquence et les facteurs favorisants du recours à la biothérapie dans de la prise en charge des patients suivis dans notre service pour une MB. Méthodes : Il s’agit d’une étude rétrospective des dossiers des patients suivis pour une MB dans un service de médecine interne de janvier 2005 à août 2018. Résultats : Un total de 41 patients a été inclus avec un âge moyen au diagnostic de 42,5 ± 12,1 ans (extrêmes de 16 ans et 63 ans) et un sex-ratio hommes/femmes égal à 1,05. L’aphtose buccale et/ou génitale était présente chez 70,7 % des patients. Les autres atteintes répertoriées étaient : oculaires (78,0 %), articulaires (46,3 %), cutanées (41,5 %), neurologiques centrales (34,1 %), vasculaires (26,8 %), digestives (7,3 %), péricardique (2,4 %) et épididymaire (2,4 %). Une biothérapie, interféron α et anticorps monoclonaux, a été utilisée chez 15 patients (36,6 %), après échec des traitements conventionnels. Les anticorps monoclonaux utilisés étaient des anti-TNFα (infliximab, adalimumab, certolizumab et golimumab) sauf chez un patient où l’ustekinumab avait été utilisé. Le recours à la biothérapie était effectué dans 46,9 % des cas ayant une atteinte oculaire et chez aucun des patient sans atteinte oculaire (p = 0,01). Conclusion : Les biothérapies représentent une solution aux échecs des traitements conventionnels dans les atteintes oculaires de la MB en particulier.

Published
2018

20. Quality of life in patients with uveitis: data from the ULISSE study (Uveitis: cLInical and medico-economic evaluation of a Standardised Strategy for the Etiological diagnosis).

Author

Bertrand, Pierre-jean, Jamilloux, Yvan, Kodjikian, Laurent, Errera, Marie-Helene, Perard, Laurent, Pugnet, Gregory, Tieulie, Nathalie, Andre, Marc, Bielefeld, Philip, Bron, Alain M., Decullier, Evelyne, Bin, Sylvie, and Seve, Pascal

Abstract

Aims To assess vision-related (VR-QOL) and healthrelated quality of life (HR-QOL) in a large series of patients with de novo uveitis at baseline and 6-month follow-up. Methods Non-inferiority, prospective, multicentre, cluster randomised controlled trial registered under the Unique Identifier: NCT01162070. VR-QOL and HR-QOL were assessed by the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) and the Medical Outcomes Study 36-item Short Form Survey (SF-36). Results At inclusion, 466 patients completed the VFQ-25. The mean composite score was 80.0 (±16.7). In multivariate analysis, higher age, female sex and insidious onset were significantly associated with lower QOL. At 6 months, 138 patients completed the VFQ-25, with a significantly higher mean composite score of 82.6 (±16.7). SF-36 mental component was 42.9 (±11.3) and physical component was 47.2 (±8.5) at inclusion (n=425). HR-QOL improvement at 6 months was not clinically significant. Conclusion QOL seems relatively well preserved in this cohort; only VR-QOL improved significantly at 6 months, especially in patients with low initial visual acuity. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

21. Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis

Author

Martin, Mickaël, primary, Martinez, Camille, additional, Arnaud, Laurent, additional, Weber, Jean-Christophe, additional, Poindron, Vincent, additional, Blaison, Gilles, additional, Kieffer, Pierre, additional, Bonnotte, Bernard, additional, Berthier, Sabine, additional, Wahl, Denis, additional, Maurier, Francois, additional, Pennaforte, Jean-Loup, additional, Bielefeld, Philip, additional, Magy-Bertrand, Nadine, additional, Devilliers, Hervé, additional, and Martin, Thierry, additional

Published
2019
Full Text
View/download PDF

22. Distal ischemia as the initial presentation of hypereosinophilic syndrome-related arterial involvement: A case study and literature review

Author

Rohmer, Julien, primary, Groh, Matthieu, additional, Samson, Maxime, additional, London, Jonathan, additional, Jachiet, Marie, additional, Rouzaud, Diane, additional, Paule, Romain, additional, Suarez, Felipe, additional, Lefèvre, Guillaume, additional, Cohen, Fleur, additional, Lambotte, Olivier, additional, Perlat, Antoinette, additional, Bielefeld, Philip, additional, Guillevin, Loïc, additional, Kahn, Jean-Emmanuel, additional, and Terrier, Benjamin, additional

Published
2019
Full Text
View/download PDF

24. Expert opinion on the use of biological therapy in non-infectious uveitis

Author

Touhami, Sara, primary, Diwo, Eléonore, additional, Sève, Pascal, additional, Trad, Salim, additional, Bielefeld, Philip, additional, Sène, Damien, additional, Abad, Sebastien, additional, Brézin, Antoine, additional, Quartier, Pierre, additional, Koné Paut, Isabelle, additional, Weber, Michel, additional, Chiquet, Christophe, additional, Errera, Marie-Hélène, additional, Sellam, Jérémie, additional, Cacoub, Patrice, additional, Kaplanski, Gilles, additional, Kodjikian, Laurent, additional, Bodaghi, Bahram, additional, and Saadoun, David, additional

Published
2019
Full Text
View/download PDF

26. Randomized controlled trial evaluating a standardized strategy for uveitis etiologic diagnosis (ULISSE)

Author

de Parisot, Audrey, Kodjikian, Laurent, Errera, Marie-Hélène, Sedira, Neila, Heron, Emmanuel, Pérard, Laurent, Cornut, Pierre-Loïc, Schneider, Christelle, Rivière, Sophie, Ollé, Priscille, Pugnet, Grégory, Cathébras, Pascal, Manoli, Pierre, Bodaghi, Bahram, Saadoun, David, Baillif, Stéphanie, Tieulie, Nathalie, ANDRE, Marc, Chiambaretta, Frédéric, BONIN, Nicolas, Bielefeld, Philip, Bron, Alain, Mouriaux, Frédéric, Bienvenu, Boris, Vicente, Stéphanie, Bin, Sylvie, Broussolle, Christiane, Decullier, Evelyne, Sève, Pascal, ULISSE group, ., Hospices Civils de Lyon (HCL), Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Hôpital Edouard Herriot [CHU - HCL], Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Pierre-Paul Riquet Hospital, Centre Hospitalier Universitaire de Purpan (CHU Purpan), North Hospital, Hôpital La Pitie Salpetriere, Hôpital l'Archet, Centre Hospitalier Universitaire Gabriel Montpied, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Caen, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts (CHNO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), and Centre National de la Recherche Scientifique (CNRS)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)

Subjects
Male, medicine.medical_specialty, Population, Visual Acuity, ophtalmologie, Tuberculin, Diagnostic Techniques, Ophthalmological, law.invention, Uveitis, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, Internal medicine, Pragmatic Clinical Trials as Topic, medicine, Humans, Prospective Studies, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, education, Prospective cohort study, 030203 arthritis & rheumatology, education.field_of_study, medicine.diagnostic_test, business.industry, Complete blood count, Middle Aged, medicine.disease, 3. Good health, Surgery, ophthalmology, Erythrocyte sedimentation rate, 030221 ophthalmology & optometry, Female, Chest radiograph, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
Abstract

PURPOSE:To prospectively assess the efficiency of a standardized diagnostic approach, compared to an open strategy, for the etiologic diagnosis of uveitis.DESIGN: Noninferiority, prospective, multicenter, clustered randomized controlled trial.METHODS: Consecutive patients with uveitis, who visited 1 of the participating departments of ophthalmology, were included. In the standardized group, all patients had a minimal evaluation regardless of the type of uveitis (complete blood count, erythrocyte sedimentation rate, C-reactive protein, tuberculin skin test, syphilis serology, and chest radiograph) followed by more complex investigations according to ophthalmologic findings. In the open group, the ophthalmologist could order any type of investigation. Main outcome was the percentage of etiologic diagnoses at 6 months.RESULTS: Nine hundred and three patients with uveitis were included from January 2010 to May 2013 and the per-protocol population comprised 676 patients (open 373; standardized 303). Mean age at diagnosis was 46 years. Anatomic distribution of uveitis was as follows: anterior (60.8% and 72.3%, P [ .0017), intermediate (11.7% and 12.3%, P [ .8028), posterior (17.8% and 8.2%, P [ .0004), and panuveitis (15.3% and 15.2%, P [ .9596). An etiologic diagnosis was established in 54.4% of cases in the open group and 49.5% in the standardized group (P [ .2029). The difference between both strategies (standardized minus open) was L4.9% (95% CI [L12.5%; 2.6%]). There were more investigations in the open group than in the standardized group (5371 vs 3759, P

Published
2017

27. Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves' Ophthalmopathy, a Report of Three Cases.

Author

Maldiney, Thomas, Deschasse, Clémence, and Bielefeld, Philip

Abstract

Purpose: To discuss the use of tocilizumab in mild to severe Graves' ophthalmopathy as corticosteroid-adjunctive therapy. Methods: Retrospective case reports.Results: Three patients with corticosteroid-resistant or advanced diplopia-associated Graves' ophthalmopathy were subsequently treated with monthly intravenous tocilizumab at a dose of 8 mg/kg. None reported a past or present history of dysthyroidism. The adjunction of interleukin-6-receptor monoclonal antibody treatment was associated with a significant improvement in ocular symptoms, notably diplopia and proptosis, and functional prognosis in all patients, with one relapse approximately two months after the end of the treatment.Conclusion: These clinical reports confirm the relative efficacy and tolerability profile of intravenous tocilizumab in severe or corticosteroid-resistant Graves' ophthalmopathy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

28. Contribution of diagnostic tests for the etiological assessment of uveitis, data from the ULISSE study (Uveitis: Clinical and medicoeconomic evaluation of a standardized strategy of the etiological diagnosis)

Author

Grumet, Pierre, primary, Kodjikian, Laurent, additional, de Parisot, Audrey, additional, Errera, Marie-Hélène, additional, Sedira, Neila, additional, Heron, Emmanuel, additional, Pérard, Laurent, additional, Cornut, Pierre-Loïc, additional, Schneider, Christelle, additional, Rivière, Sophie, additional, Ollé, Priscille, additional, Pugnet, Grégory, additional, Cathébras, Pascal, additional, Manoli, Pierre, additional, Bodaghi, Bahram, additional, Saadoun, David, additional, Baillif, Stéphanie, additional, Tieulie, Nathalie, additional, Andre, Marc, additional, Chiambaretta, Frédéric, additional, Bonin, Nicolas, additional, Bielefeld, Philip, additional, Bron, Alain, additional, Mouriaux, Frédéric, additional, Bienvenu, Boris, additional, Vicente, Stéphanie, additional, Bin, Sylvie, additional, Labetoulle, Marc, additional, Broussolle, Christiane, additional, Jamilloux, Yvan, additional, Decullier, Evelyne, additional, and Sève, Pascal, additional

Published
2018
Full Text
View/download PDF

29. Uveitis: Diagnostic work-up. A literature review and recommendations from an expert committee

Author

Sève, Pascal, primary, Cacoub, Patrice, additional, Bodaghi, Bahram, additional, Trad, Salim, additional, Sellam, Jérémie, additional, Bellocq, David, additional, Bielefeld, Philip, additional, Sène, Damien, additional, Kaplanski, Gilles, additional, Monnet, Dominique, additional, Brézin, Antoine, additional, Weber, Michel, additional, Saadoun, David, additional, Chiquet, Christophe, additional, and Kodjikian, Laurent, additional

Published
2017
Full Text
View/download PDF

30. Efficacy and safety of tumor necrosis factor antagonists in refractory sarcoidosis: A multicenter study of 132 patients

Author

Jamilloux, Yvan, primary, Cohen-Aubart, Fleur, additional, Chapelon-Abric, Catherine, additional, Maucort-Boulch, Delphine, additional, Marquet, Alicia, additional, Pérard, Laurent, additional, Bouillet, Laurence, additional, Deroux, Alban, additional, Abad, Sébastien, additional, Bielefeld, Philip, additional, Bouvry, Diane, additional, André, Marc, additional, Noel, Nicolas, additional, Bienvenu, Boris, additional, Proux, Alice, additional, Vukusic, Sandra, additional, Bodaghi, Bahram, additional, Sarrot-Reynauld, Françoise, additional, Iwaz, Jean, additional, Amoura, Zahir, additional, Broussolle, Christiane, additional, Cacoub, Patrice, additional, Saadoun, David, additional, Valeyre, Dominique, additional, and Sève, Pascal, additional

Published
2017
Full Text
View/download PDF

31. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: Multicenter study from the french uveitis network

Author

Vallet , Hélène, Seve , Pascal, Biard , Lucie, Fraison , Jean-Baptiste, Bielefeld , Philip, Perard , Laurent, Bienvenu , Boris, Abad , Sébastien, Rigolet , Aude, Deroux , Alban, Sène , Damien, Perlat , Antoinette, Marie , Isabelle, Feurer , Elodie, Hachulla , Eric, Fain , Olivier, Clavel , Gaëlle, Riviere , Sophie, Bouche , Pierre-Alban, Gueudry , Julie, Pugnet , Gregory, Le Hoang , Phuc, Resche Rigon , Matthieu, Cacoub , Patrice, Bodaghi , Bahram, Saadoun , David, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), E14, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Department of Internal Medicine, Hospices Civils de Lyon, Université de Lyon, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Jean Verdier [AP-HP], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Edouard Herriot [CHU - HCL], Service de médecine interne [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpital Avicenne [AP-HP], Centre de recherche en myologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Association française contre les myopathies (AFM-Téléthon)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris] (DHU - I2B), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Université Pierre et Marie Curie - Paris 6 (UPMC), Hôpital Michallon, Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], CHU Pontchaillou [Rennes], Service de Médecine Interne [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases (LYOS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine interne [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Saint-Antoine [AP-HP], ROTHSCHILD FOUNDATION, CHU de Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de Médecine Interne, Centre Hospitalier Universitaire de Toulouse, PRES Université de Toulouse, Service de Néphrologie et Immunopathologie Clinique, Centre Hospitalier Universitaire de Toulouse, Immunologie - Immunopathologie - Immunothérapie (I3), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Immunologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Ophtalmologie [CHU Pitié-Salpêtrière], The authors would like to thank Emmanuel Heron, Nathalie Tieulie, Gilles Blaison, Yoland Schoindre, Guillaume Moulis, Thomas Papo, Olivier Lidove, and Jean Sibilia for their collaboration and for follow-up of patients., Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Fondation Ophtalmologique Adolphe de Rothschild [Paris], Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service Médecine interne et immunopathologie clinique [CHU Toulouse], Pôle IUCT [CHU Toulouse], CHU Pitié-Salpêtrière [APHP], Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Department of Internal Medicine, Hospices Civils de Lyon, Hôpital Saint Louis (Hôpital Saint Louis), Assistance Publique - Hôpitaux de Paris, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), Hôpital Jean Verdier AP-HP Bondy, Hôpital Jean Verdier [Bondy], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Hôpital avicenne, Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Avicenne, Université Pierre et Marie Curie - Paris 6 (UPMC)-CHU Pitié-Salpêtrière [APHP], Université Grenoble Alpes (UGA), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7), Service de médecine interne, Service de Médecine Interne [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, CHU Saint-Antoine [APHP], Service d'immunologie [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Service d'ophtalmologie [CHU Pitié-Salpêtrière], Université Pierre et Marie Curie - Paris 6 (UPMC)-CHU Pitié-Salpêtrière [AP-HP], Jonchère, Laurent, Hospices Civils de Lyon ( HCL ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Department of Internal Medicine, Hospices Civils de Lyon, Hôpital Saint Louis ( Hôpital Saint Louis ), Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité ( CRESS (U1153 / UMR_A 1125) ), Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Recherche Agronomique ( INRA ), Hôpital Jean Verdier, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Division of Internal Medicine, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne-Université Paris 13 ( UP13 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Association française contre les myopathies ( AFM-Téléthon ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris] ( DHU - I2B ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -CHU Pitié-Salpêtrière [APHP], Hôpital Michallon, CHU Grenoble, Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 ( UPD7 ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -CHU Rouen, Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases ( LYOS ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Immunologie - Immunopathologie - Immunothérapie ( I3 ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), and Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP]

Subjects
Adult, Male, safety, [SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication, anti-TNFα, Tumor Necrosis Factor-alpha, [ SDV.SP.MED ] Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Behcet Syndrome, Remission Induction, efficacy, Adalimumab, Anti-Inflammatory Agents, [ SDV.IMM.IMM ] Life Sciences [q-bio]/Immunology/Immunotherapy, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, refractory inflammatory uveitis, Infliximab, Uveitis, Young Adult, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, [SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organs, [ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory Organs, Humans, Female, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs
Abstract

To analyze the factors associated with response to anti-tumor necrosis factor (anti-TNF) treatment and compare the efficacy and safety of infliximab (IFX) and adalimumab (ADA) in patients with refractory noninfectious uveitis.This was a multicenter observational study of 160 patients (39% men and 61% women; median age 31 years [interquartile range 21-42]) with uveitis that had been refractory to other therapies, who were treated with anti-TNF (IFX 5 mg/kg at weeks 0, 2, 6, and then every 5-6 weeks [n = 98] or ADA 40 mg every 2 weeks [n = 62]). Factors associated with complete response were assessed by multivariate analysis. Efficacy and safety of IFX versus ADA were compared using a propensity score approach with baseline characteristics taken into account. Subdistribution hazard ratios (SHRs) and 95% confidence intervals (95% CIs) were calculated.The main etiologies of uveitis included Behçet's disease (BD) (36%), juvenile idiopathic arthritis (22%), spondyloarthropathy (10%), and sarcoidosis (6%). The overall response rate at 6 and 12 months was 87% (26% with complete response) and 93% (28% with complete response), respectively. The median time to complete response was 2 months. In multivariate analysis, BD and occurrence of5 uveitis flares before anti-TNF initiation were associated with complete response to anti-TNF (SHR 2.52 [95% CI 1.35-4.71], P = 0.004 and SHR 1.97 [95% CI 1.02-3.84], P = 0.045, respectively). Side effects were reported in 28% of patients, including serious adverse events in 13%. IFX and ADA did not differ significantly in terms of occurrence of complete response (SHR 0.65 [95% CI 0.25-1.71], P = 0.39), serious side effects (SHR 0.22 [95% CI 0.04-1.25], P = 0.089), or event-free survival (SHR 0.55 [95% CI 0.28-1.08], P = 0.083).Anti-TNF treatment is highly effective in refractory inflammatory uveitis. BD is associated with increased odds of response. IFX and ADA appear to be equivalent in terms of efficacy.

Published
2016

32. CA176 - Intérêt de l’ustékinumab pour le traitement des uvéites antérieures chez une patiente avec un rhumatisme psoriasique

Author

Bielefeld, Philip, Picque, J. B., Devilliers, Hervé, Maupin, E., Baudin, F., Turcu, A., Muller, Géraldine, Bron, Alain, Creuzot Garcher, Catherine, Besancenot, Jean-François, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation (CSGA), and Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

National audience; Introduction Une patiente de 36ans présente un rhumatisme psoriasique depuis 15 ans, assez calme puisque sensible aux anti-inflammatoires non stéroïdiens, avec peu de manifestations cutanées. Observation Les uvéites antérieures récidivantes posent problème chez cette patiente avec au moins 3 épisodes par an, avec extension au pôle postérieur et nécessité d’une corticothérapie orale à chaque poussée. Un traitement de fond par méthotrexate ne prévient pas les récidives. Un traitement par anti-TNF est tenté, tout d’abord des perfusions d’infliximab, qui se soldent dès la troisième par des éruptions cutanées prurigineuses. Un remplacement par adalimumab provoque le même effet secondaire allergique. Il est décidé de changer de classe de biothérapie, par crainte de la récidive de cet effet secondaire avec un autre anti-TNF. L’ustékinumab est introduit à la dose de 45mg selon le schéma classique, avec une excellente tolérance. Aucune récidive d’uvéite n’est survenue au bout d’un an de traitement. Discussion L’ustékinumab est un inhibiteur des interleukines IL-12 et IL-23 agissant contre la sous-unité P40 commune à l’IL-12/23. Si la place de l’ustékinumab dans le traitement du rhumatisme psoriasique demande à être précisée, on sait que l’interleukine-23 intervient dans la pathogénie des uvéites inflammatoires [1]. Conclusion Il n’existe pour le moment pas de protocole d’essai de ce médicament pour les uvéites résistantes aux anti-TNF, ou les patients avec inflammation oculaire sévère intolérants aux anti-TNF. Une évaluation à plus grande échelle serait nécessaire.

Published
2015

33. Reply

Author

de Parisot, Audrey, primary, Jamilloux, Yvan, additional, Kodjikian, Laurent, additional, Errera, Marie-Hélène, additional, Sedira, Neila, additional, Heron, Emmanuel, additional, Pérard, Laurent, additional, Cornut, Pierre-Loïc, additional, Schneider, Christelle, additional, Rivière, Sophie, additional, Ollé, Priscille, additional, Pugnet, Grégory, additional, Cathébras, Pascal, additional, Manoli, Pierre, additional, Bodaghi, Bahram, additional, Saadoun, David, additional, Baillif, Stéphanie, additional, Tieulie, Nathalie, additional, Andre, Marc, additional, Chiambaretta, Frédéric, additional, Bonin, Nicolas, additional, Bielefeld, Philip, additional, Bron, Alain, additional, Mouriaux, Frédéric, additional, Bienvenu, Boris, additional, Vicente, Stéphanie, additional, Bin, Sylvie, additional, Broussolle, Christiane, additional, Decullier, Evelyne, additional, and Sève, Pascal, additional

Published
2017
Full Text
View/download PDF

34. Intérêt de l’interféron pégylé alpha 2a dans le traitement des uvéites de la maladie de Behçet : à propos de 5 patients

Author

Deschasse, Clémence, Devilliers, Hervé, Bour, J.-B., Legendre, M., Bohm, A., Arbault, A., Martin Phips, T., Muselier, Aurore, Bron, Alain M., Besancenot, Jean-François, Bielefeld, Philip, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation (CSGA), Institut National de la Recherche Agronomique (INRA)-Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS), and Société nationale française de médecine interne (SNFMI)

Subjects
business.industry, [SDV.BA]Life Sciences [q-bio]/Animal biology, Gastroenterology, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, 030221 ophthalmology & optometry, Internal Medicine, Medicine, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], 030211 gastroenterology & hepatology, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, business, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2014

36. Potential of Pegylated Interferon Alpha-2a in Behçet Uveitis: A Report of Five Cases.

Author

Bielefeld, Philip, Devilliers, Hervé, Deschasse, Clémence, Saadoun, David, Sève, Pascal, Muselier, Aurore, Creuzot-Garcher, Catherine, Besancenot, Jean-François, and Bron, Alain Marie

Subjects
*INTERFERON alpha, *BEHCET'S disease, *THERAPEUTICS, *THERAPEUTIC use of proteins, *RECOMBINANT proteins, *ANTIVIRAL agents, *POLYETHYLENE glycol, *SUBCUTANEOUS injections, *VISUAL acuity, *DIAGNOSIS
Abstract

A letter to the editor is presented regarding the therapeutic potential of pegylated interferon (peg-IFN) alpha-2a for Behçet uveitis treatment.

Published
2016
Full Text
View/download PDF

40. Mesure systématique des index de pression systolique à la cheville pour le dépistage de l’artériopathie oblitérante des membres inférieurs dans les services de médecine interne : comparaison aux recommandations de la Haute Autorité de santé. Étude prospective descriptive chez 106 patients

Author

Vinit, Julien, primary, Bielefeld, Philip, additional, Muller, Géraldine, additional, Bonnotte, Bernard, additional, Lorcerie, Bernard, additional, Besancenot, Jean-François, additional, and Terriat, Béatrice, additional

Published
2011
Full Text
View/download PDF

42. Cotrimoxazole as a Treatment for Recurrent Idiopathic Anterior Scleritis: A Single-center Experience in 20 Patients.

Author

Bielefeld, Philip, Muselier, Aurore, Devilliers, Hervé, Creuzot-Garcher, Catherine, Muller, Géraldine, Besancenot, Jean-François, and Bron, Alain M.

Subjects
*CO-trimoxazole, *SCLERITIS, *NONSTEROIDAL anti-inflammatory agents, *GLAUCOMA, *KERATITIS, *SULFAMETHOXAZOLE
Abstract

The article discusses research conducted by Philip Bielefeld, Aurure Muselier and Alain M. Bron on 20 patients suffering from Anterior Scleritis by treating the patients with Cotrimoxazole(CTX), a corticosteriod- sparing agent by means of its immunomodulatory properties as an alternative to nonsteroidal anti-flammatory drug(NSAID). Out of 20 patients, 16 have responded successfully with no side effects and proving the treatment as promising with a good balance between safety and efficacy.

Published
2015
Full Text
View/download PDF

44. Vasculitis in the Very Elderly

Author

Turcu, Alin, primary, Bielefeld, Philip, additional, Besancenot, Jean-François, additional, Lorcerie, Bernard, additional, and Pfitzenmeyer, Pierre, additional

Published
2002
Full Text
View/download PDF

45. Characteristics of Adult Patients with Idiopathic Retroperito-Neal Fibrosis and Assessment of Risk of Relapse at Diagnosis.

Author

Razanamahery, Jerome, Bouldoires, Bastien, Humbert, Sebastien, Bielefeld, Philip, Fournier, Veronique, Bonnotte, Bernard, Blaison, Gilles, Magy-Bertrand, Nadine, and Ooi, Keith

Subjects
CHRONIC kidney failure, RISK assessment, RETROPERITONEAL fibrosis, SMOKING cessation, DIAGNOSIS, ADULTS
Abstract

Objectives: To compare adult patients' characteristics suffering from idiopathic retroperitoneal fibrosis between "relapse-free" and relapsing patients at the diagnosis and identify factors associated with relapse at initial presentation. Methods: We conducted a retrospective multicentric study in four hospitals in Eastern France, from 1993 to 2020, of adult patients suffering from idiopathic retroperitoneal fibrosis. We analyzed clinical, biological, and radiological features at diagnosis and during a forty-month follow-up. Results: Of 47 patients suffering from retroperitoneal fibrosis, 21 patients had idiopathic retroperitoneal fibrosis. Among them, 13 experienced one or more relapses during follow-up. At diagnosis, clinical characteristics, relevant comorbidities, biological and radiological features were similar between groups. Smoking cessation seems associated with decreased relapse risk (p: 0.0624). A total of 8 patients developed chronic renal failure during follow-up. Ureteral infiltration at diagnosis was associated with evolution to chronic renal failure (p: 0.0091). Conclusion: No clinical, biological, or radiological features could predict relapse at retroperitoneal fibrosis diagnosis, but smoking cessation may prevent relapse. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

46. Cotrimoxazole as a Treatment for Recurrent Idiopathic Anterior Scleritis: A Single-center Experience in 20 Patients

Author

Catherine Creuzot-Garcher, Philip Bielefeld, Alain M. Bron, A. Muselier, Hervé Devilliers, Jean-François Besancenot, Géraldine Muller, Bielefeld, Philip, Department of Internal Medicine and Systemic Diseases, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Department of Ophthalmology, and Institut National de la Recherche Agronomique (INRA)

Subjects
Adult, Male, medicine.medical_specialty, Organes des sens, Sensory Organs, Médecine humaine et pathologie, Single Center, episcleritis, wegeners-granulomatosis, Trimethoprim, Sulfamethoxazole Drug Combination, medicine, Anterior scleritis, Humans, Immunology and Allergy, trimethoprim, [SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organs, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Middle Aged, medicine.disease, Surgery, Ophthalmology, Rheumatoid arthritis, Female, Human health and pathology, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Immunosuppressive Agents, Scleritis
Abstract

Anterior scleritis presentations range from a benign course to severe cases such as scleral necrosis. About one-third of cases are associated with systemic diseases, mainly rheumatoid arthritis and...

Published
2014

47. Evaluating the cost-consequence of a standardized strategy for the etiological diagnosis of uveitis (ULISSE study).

Author

de Parisot A, Jamilloux Y, Kodjikian L, Errera MH, Sedira N, Heron E, Pérard L, Cornut PL, Schneider C, Rivière S, Ollé P, Pugnet G, Cathébras P, Manoli P, Bodaghi B, Saadoun D, Baillif S, Tieulie N, André M, Chiambaretta F, Bonin N, Bielefeld P, Bron A, Mouriaux F, Bienvenu B, Amamra N, Guerre P, Decullier E, and Sève P

Subjects
Adult, Female, France, Humans, Male, Middle Aged, Ophthalmologists, Ophthalmology economics, Practice Patterns, Physicians' economics, Practice Patterns, Physicians' standards, Prospective Studies, Uveitis etiology, Ophthalmology standards, Uveitis diagnosis, Uveitis economics
Abstract

Main Objective: To prospectively assess the cost-consequence of a standardized diagnostic strategy as to compared to an open one for the etiological diagnosis of uveitis., Design: This was a prospective, non-inferiority, multicentre, randomized controlled trial., Methods: We included all consecutive patients with uveitis who had visited at least one of the Departments of Ophthalmology. In the standardized group, patients had a minimal work-up regardless of the type of uveitis (including evaluation of the CBC, ESR, C-reactive protein, tuberculin skin test, syphilis serology and chest X-ray). Depending on ophthalmological findings, further investigations could be performed. In the open strategy, ophthalmologists were free to order any kind of investigation. The main outcome was the mean cost per patient of each strategy., Results: 903 uveitis patients were included from January, 2010 to May, 2013. The mean cost per patient of the standardized strategy was 182.97 euros [CI 95% (173.14; 192.80)], and the mean cost per patient of the open strategy was 251.75 euros [CI 95% (229.24; 274.25)]. Therefore, the mean cost per patient of the standardized strategy was significantly lower than the mean cost per patient of the open strategy (p<0.001). There were significantly fewer visits (p<0.001), fewer radiological procedures (p<0.004) and fewer laboratory investigations (p<0.001) in the standardized group., Conclusion: A standardized strategy is a cost-saving approach for the etiological diagnosis of uveitis., Competing Interests: The authors have declared that no competing interests exist.

Published
2020
Full Text
View/download PDF

48. Outcome of patients with sarcoidosis refractory to TNF antagonists: a case series.

Author

Thery-Casari C, Jamilloux Y, Bouvry D, Chapelon-Abric C, Marquet A, Bielefeld P, Schleinitz N, Vukusic S, Girszyn N, Fain O, Bonnet F, Valeyre D, and Seve P

Abstract

Background: Tumor necrosis factor (TNF) antagonists have been reported as an efficient third-line therapy for sarcoidosis but there is no data regarding patients who do not respond to this treatment. Objective: To report the characteristics, the outcome and the response to therapy of patients with sarcoidosis resistant to TNF antagonists. Methods: Patients from the French STAT (Sarcoidosis Treatment with Anti-TNF) registry who were classified as non-responders and who were followed-up for >1 year were included. The response to further therapies was classified as complete response, or partial response, and the others were classified as non-responders. Results: Among the 132 patients from the registry, 14 were considered as non-responders to anti-TNF. Nine patients (66% of women; mean age 48 years) were analyzed. The mean number of organs involved was 4.2. Seven patients were previously treated with more than 2 immunosuppressive treatments. The mean duration of the anti-TNF treatment was 9 months (range, 3-24). After a mean follow-up duration of 58 months (median, 35; range, 19-128) a complete response was observed in 2/9 cases, a partial response in 5/9 cases, and 2/9 cases were considered as non-responders. In all but one patient, the immunosuppressant that allowed the clinical response had previously been used. Furthermore, the dosage was not necessarily increased to gain efficacy. Non-responders were treated by corticosteroids only because of their comorbidities or noncompliance. Conclusion: In patients who do not respond to TNF antagonists, previously used immunosuppressants may be useful. Excluding a differential diagnosis, assessing compliance and testing for anti-drug antibodies should be systematic. (Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 371-375) ., (Copyright: © 2018 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES.)

Published
2018
Full Text
View/download PDF

49. Randomized Controlled Trial Evaluating a Standardized Strategy for Uveitis Etiologic Diagnosis (ULISSE).

Author

de Parisot A, Kodjikian L, Errera MH, Sedira N, Heron E, Pérard L, Cornut PL, Schneider C, Rivière S, Ollé P, Pugnet G, Cathébras P, Manoli P, Bodaghi B, Saadoun D, Baillif S, Tieulie N, Andre M, Chiambaretta F, Bonin N, Bielefeld P, Bron A, Mouriaux F, Bienvenu B, Vicente S, Bin S, Broussolle C, Decullier E, and Sève P

Subjects
Female, Humans, Male, Middle Aged, Prospective Studies, Visual Acuity, Diagnostic Techniques, Ophthalmological standards, Pragmatic Clinical Trials as Topic, Uveitis diagnosis
Abstract

Purpose: To prospectively assess the efficiency of a standardized diagnostic approach, compared to an open strategy, for the etiologic diagnosis of uveitis., Design: Noninferiority, prospective, multicenter, clustered randomized controlled trial., Methods: Consecutive patients with uveitis, who visited 1 of the participating departments of ophthalmology, were included. In the standardized group, all patients had a minimal evaluation regardless of the type of uveitis (complete blood count, erythrocyte sedimentation rate, C-reactive protein, tuberculin skin test, syphilis serology, and chest radiograph) followed by more complex investigations according to ophthalmologic findings. In the open group, the ophthalmologist could order any type of investigation. Main outcome was the percentage of etiologic diagnoses at 6 months., Results: Nine hundred and three patients with uveitis were included from January 2010 to May 2013 and the per-protocol population comprised 676 patients (open 373; standardized 303). Mean age at diagnosis was 46 years. Anatomic distribution of uveitis was as follows: anterior (60.8% and 72.3%, P = .0017), intermediate (11.7% and 12.3%, P = .8028), posterior (17.8% and 8.2%, P = .0004), and panuveitis (15.3% and 15.2%, P = .9596). An etiologic diagnosis was established in 54.4% of cases in the open group and 49.5% in the standardized group (P = .2029). The difference between both strategies (standardized minus open) was -4.9% (95% CI [-12.5%; 2.6%]). There were more investigations in the open group than in the standardized group (5371 vs 3759, P < .0001)., Conclusion: The standardized strategy appears to be an efficient diagnostic approach for the etiologic diagnosis of uveitis, although its noninferiority cannot be proved., (Copyright © 2017 Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

50. Efficacy and safety of TNF antagonists in ocular sarcoidosis: data from the French registry STAT.

Author

Marquet A, Chapelon-Abric C, Maucort-Boulch D, Cohen-Aubart F, Pérard L, Bouillet L, Abad S, Bielefeld P, Bouvry D, André M, Noël N, Bienvenu B, Proux A, Vukusic S, Bodaghi B, Sarrot-Reynaud F, Iwaz J, Broussolle C, Saadoun D, Jamilloux Y, Valeyre D, and Sève P

Abstract

Backgroung: This study investigated the efficacy and safety of TNF antagonists in sarcoid uveitis in unselected cases. Design: This is a multicentre study on patients with sarcoidosis who received TNF antagonists in pneumology and internal medicine departments in France. We present here the subgroup of patients with biopsy-proven sarcoid uveitis included in the nationwide registry STAT (Sarcoidosis treated with TNF AnTagonists). Results: Among the 132 patients included in this multicenter study, 18 patients with refractory uveitis were treated as a first-line TNF antagonist with infliximab (n=14), adalimumab (n=3) and certolizumab (n=1). Before anti-TNF initiation, the median duration of sarcoidosis was 42 months and 83% of the patients have been treated with at least one immunosuppressive drug. Six patients switched for a second-line TNF antagonist. After a mean time under treatment of 29 months, the treatment resulted in a significant decrease of the ophthalmic extrapulmonary Physician Organ Severity Tool (ePOST) (mean score: 4.2 vs. 2.6) scores and a steroid sparing effect (29.4±20.7 vs. 6.2±5.2 mg/d). Overall, the ophthalmic response, either complete or partial, was 67%. Nine patients (50%) presented adverse events, including severe infectious complications in 5 patients, which required anti-TNF treatment interruption in 6 cases (33%). Among the 7 responder patients who discontinued anti-TNF therapy, 71% relapsed. Finally, 12 patients (67%) could continue TNF antagonist treatment. Conclusions: TNF antagonists were efficient in 67% of biopsy-proven refractory sarcoid uveitis. Severe adverse events, mainly infectious complications, were frequent. The high frequency of relapses after anti-TNF-α discontinuation requires a close patient follow-up thereafter. (Sarcoidosis Vasc Diffuse Lung Dis 2017; 34: 74-80) ., (Copyright: © 2017.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results